scholarly journals Role of equilibrative nucleoside transporter 1 in AKI

2012 ◽  
Vol 8 (4) ◽  
pp. 192-192
Keyword(s):  
Nucleoside Transporter ◽  
Equilibrative Nucleoside Transporter

scholarly journals The role of the equilibrative nucleoside transporter 1 on tissue and fetal distribution of ribavirin in the mouse

2016 ◽  
Vol 37 (6) ◽  
pp. 336-344 ◽  
Author(s):  
Christopher J. Endres ◽  
Aaron M. Moss ◽  
Kazuya Ishida ◽  
Rajgopal Govindarajan ◽  
Jashvant D. Unadkat
Keyword(s):  
Nucleoside Transporter ◽  
Equilibrative Nucleoside Transporter

scholarly journals Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer

ISRN Oncology ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Shuji Komori ◽  
Shinji Osada ◽  
Kazuhiro Yoshida
Keyword(s):  
Pancreatic Cancer ◽  
Advanced Pancreatic Cancer ◽  
Metabolic Enzymes ◽  
Interindividual Variation ◽  
Nucleoside Transporter ◽  
Standard Drug ◽  
Equilibrative Nucleoside Transporter ◽  
Nucleotide Pools ◽  
Novel Strategy

5-fluorouracil (5-FU) is widely used in chemotherapy for gastric and colorectal cancer, but gemcitabine (GEM), and not 5-FU, is approved as a standard drug for use in pancreatic cancer. Interindividual variation in the enzyme activity of the GEM metabolic pathway can affect the extent of GEM metabolism and the efficacy of GEM chemotherapy. Human equilibrative nucleoside transporter 1 (hENT1) is recognized as a major transporter of GEM into cells. In addition, a factor that activates hENT1 is the inhibition of thymidylate synthase (TS), one of the 5-FU metabolic enzymes; TS inhibition mediates depleting intracellular nucleotide pools, resulting in the activation of the salvage pathway mediated through hENT1. In this paper, the role of 5-FU in GEM-based chemotherapy for pancreatic cancer is discussed with special emphasis on enzymes involved in the 5-FU and GEM metabolic pathways and in the correlation between GEM responsiveness and the expression of 5-FU and GEM metabolic enzymes.

scholarly journals Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities

2020 ◽  
Vol 11 ◽  
Author(s):  
Jonathan D. Geiger ◽  
Nabab Khan ◽  
Madhuvika Murugan ◽  
Detlev Boison
Keyword(s):  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Adenosine Kinase ◽  
Nucleoside Transporter ◽  
The Novel ◽  
Equilibrative Nucleoside Transporter ◽  
Novel Coronavirus ◽  
End Stage

The outbreak of the novel coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) requires urgent clinical interventions. Crucial clinical needs are: 1) prevention of infection and spread of the virus within lung epithelia and between people, 2) attenuation of excessive lung injury in Advanced Respiratory Distress Syndrome, which develops during the end stage of the disease, and 3) prevention of thrombosis associated with SARS-CoV-2 infection. Adenosine and the key adenosine regulators adenosine deaminase (ADA), adenosine kinase (ADK), and equilibrative nucleoside transporter 1 may play a role in COVID-19 pathogenesis. Here, we highlight 1) the non-enzymatic role of ADA by which it might out-compete the virus (SARS-CoV-2) for binding to the CD26 receptor, 2) the enzymatic roles of ADK and ADA to increase adenosine levels and ameliorate Advanced Respiratory Distress Syndrome, and 3) inhibition of adenosine transporters to reduce platelet activation, thrombosis and improve COVID-19 outcomes. Depending on the stage of exposure to and infection by SARS-CoV-2, enhancing adenosine levels by targeting key adenosine regulators such as ADA, ADK and equilibrative nucleoside transporter 1 might find therapeutic use against COVID-19 and warrants further investigation.

New role of the human equilibrative nucleoside transporter 1 (hENT1) in Epithelial-to-mesenchymal transition in renal tubular cells

2012 ◽  
Vol 227 (4) ◽  
pp. 1521-1528 ◽  
Author(s):  
Elena Guillén-Gómez ◽  
Itziar Pinilla-Macua ◽  
Sandra Pérez-Torras ◽  
Doo-Sup Choi ◽  
Yolanda Arce ◽  
...  
Keyword(s):  
Epithelial To Mesenchymal Transition ◽  
Nucleoside Transporter ◽  
Mesenchymal Transition ◽  
Equilibrative Nucleoside Transporter ◽  
Tubular Cells ◽  
Renal Tubular Cells ◽  
Renal Tubular

scholarly journals Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice

2019 ◽  
Vol 7 (6) ◽  
Author(s):  
Jason T. Anderson ◽  
Shuiying Hu ◽  
Qiang Fu ◽  
Sharyn D. Baker ◽  
Alex Sparreboom
Keyword(s):  
Nucleoside Transporter ◽  
Equilibrative Nucleoside Transporter
Sign in / Sign up

Export Citation Format

Share Document